Article: Drugmaker readies son of Claritin; New Schering-Plough allergy drug will likely bear the Clarinex name.(Brief Article)

Schering-Plough's Corp.'s so-called son of Claritin will resemble its predecessor quite a bit. Schering-Plough hopes to dub the blockbuster allergy drug's successor Clarinex, according to people familiar with the matter. Schering-Plough is awaiting approval from the U.S. Food & Drug Administration on the new drug, which could come this fall. The company is also waiting for FDA clearance to use the name Clarinex. A company spokesman declined to comment. By choosing a name similar to Claritin, Schering-Plough hopes to capitalize on the near-ubiquitous physician and consumer recognition of Claritin as it markets the drug's successor. Some industry observers, however, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!